| ［1］ |
黄韬, 梁云生, 陆前进. 特应性皮炎的发病机制及其治疗现状. 中国医师杂志, 2016,18（2）:161⁃164. doi: 10.3760/cma.j.issn.1008⁃1372.2016.02.001.<br />
|
| ［2］ |
Velculescu VE, Zhang L, Zhou W, et al. Characterization of the yeast transcriptome［J］. Cell, 1997,88（2）:243⁃251.<br />
|
| ［3］ |
Streets AM, Zhang X, Cao C, et al. Microfluidic single⁃cell whole⁃transcriptome sequencing［J］. Proc Natl Acad Sci U S A［J］. 2014,111（19）:7048⁃7053. doi: 10.1073/pnas.1402030111.<br />
|
| ［4］ |
Bao L, Zhang H, Mohan GC, et al. Differential of inflammation⁃related genes in IL⁃4 transgenic mice before and after the onset of atopic dermatitis skin lesions［J］. Mol Cell Probes, 2016,30（1）:30⁃38. doi: 10.1016/j.mcp.2015.11.001.<br />
|
| ［5］ |
Santoro D, Marsella R, Ahrens K, et al. Altered mRNA and protein of filaggrin in the skin of a canine animal model for atopic dermatitis［J］. Vet Dermatol, 2013,24（3）:329⁃336, e73. doi: 10.1111/vde.12031.<br />
|
| ［6］ |
Esparza⁃Gordillo J, Weidinger S, Fölster⁃Holst R, et al. A common variant on chromosome 11q13 is associated with atopic dermatitis［J］. Nat Genet, 2009,41（5）:596⁃601. doi: 10.1038/ng.347.<br />
|
| ［7］ |
Merryman⁃Simpson AE, Wood SH, Fretwell N, et al. Gene （mRNA） in canine atopic dermatitis: microarray analysis［J］. Vet Dermatol, 2008,19（2）:59⁃66. doi: 10.1111/j.1365⁃3164.2008.00653.x.<br />
|
| ［8］ |
Kim S, Kim HJ, Yang HS, et al. IL⁃31 Serum Protein and tissue mRNA levels in patients with atopic dermatitis［J］. Ann Dermatol, 2011,23（4）:468⁃473. doi: 10.5021/ad.2011.23.4. 468.<br />
|
| ［9］ |
Hamza AM, Omar SS, Abo ERA, et al. Expression levels of transcription factor PU.1 and interleukin⁃9 in atopic dermatitis and their relation to disease severity and eruption types［J］. Int J Dermatol, 2017,56（5）:534⁃539. doi: 10.1111/ijd.13579.<br />
|
| ［10］ |
Suárez⁃Fariñas M, Ungar B, Correa da Rosa J, et al. RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications［J］. J Allergy Clin Immunol, 2015,135（5）:1218⁃27. doi: 10.1016/j.jaci.2015.03.003.<br />
|
| ［11］ |
Ewald DA, Malajian D, Krueger JG, et al. Meta⁃analysis derived atopic dermatitis （MADAD） transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways［J］. BMC Med Genomics, 2015,8:60. doi: 10.1186/s12920⁃015⁃0133⁃x.<br />
|
| ［12］ |
Liang J, Liu Y, Xue R, et al. Interleukin 4 ⁃590C/T （rs2243250） polymorphism is associated with increased risk of atopic dermatitis: meta⁃analysis of case⁃control studies［J］. Dermatitis, 2017,28（2）:144⁃151. doi: 10.1097/DER.0000000000000265.<br />
|
| ［13］ |
Gittler JK, Shemer A, Suárez⁃Fariñas M，et al. Progressive activation of Th2/Th22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis［J］. J Allergy Clin Immunol, 2012,130（6）:1344⁃1354. doi: 10.1016/j.jaci. 2012.07.012.<br />
|
| ［14］ |
Sonkoly E, Janson P, Majuri ML, et al. MiR⁃155 is overexpressed in patients with atopic dermatitis and modulates T⁃cell proli⁃ferative responses by targeting cytotoxic T lymphocyte⁃associated antigen 4［J］. J Allergy Clin Immunol, 2010,126（3）:581⁃589.e1⁃20. doi: 10.1016/j.jaci.2010.05.045.<br />
|
| ［15］ |
Sonkoly E, Pivarcsi A. Advances in microRNAs: implications for immunity and inflammatory diseases［J］. J Cell Mol Med, 2009,13（1）:24⁃38. doi: 10.1111/j.1582⁃4934.2008.00534.x.<br />
|
| ［16］ |
Ma L, Xue HB, Wang F, et al. MicroRNA⁃155 may be involved in the pathogenesis of atopic dermatitis by modulating the differentiation and function of T helper type 17 （Th17） cells［J］. Clin Exp Immunol, 2015,181（1）:142⁃149. doi: 10.1111/cei. 12624.<br />
|
| ［17］ |
Rebane A, Runnel T, Aab A, et al. MicroRNA⁃146a alleviates chronic skin inflammation in atopic dermatitis through suppres⁃sion of innate immune responses in keratinocytes［J］. J Allergy Clin Immunol, 2014,134（4）:836⁃847.e11. doi: 10.1016/j.jaci. 2014.05.022.<br />
|
| ［18］ |
Chen XF, Zhang LJ, Zhang J, et al. MiR⁃151a is involved in the pathogenesis of atopic dermatitis by regulating interleukin⁃12 receptor β2［J］. Exp Dermatol, 2016. doi: 10.1111/exd.13276.<br />
|
| ［19］ |
Ghosh D, Ding L, Sivaprasad U, et al. Multiple transcriptome data analysis reveals biologically relevant atopic dermatitis signature genes and pathways［J］. PLoS One, 2015,10（12）:e0144316. doi: 10.1371/journal.pone.0144316.<br />
|
| ［20］ |
Rouaud⁃Tinguely P, Boudier D, Marchand L, et al. From the morphological to the transcriptomic characterization of a compromised three⁃dimensional in vitro model mimicking atopic dermatitis［J］. Br J Dermatol, 2015,173（4）:1006⁃1014. doi: 10.1111/bjd.14012.<br />
|
| ［21］ |
Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate⁃to⁃severe atopic dermatitis［J］. N Engl J Med, 2014,371（2）:130⁃139. doi: 10.1056/NEJMoa1314768.<br />
|
| ［22］ |
Simpson EL, Bieber T, Guttman⁃Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis［J］. N Engl J Med, 2016,375（24）:2335⁃2348. doi: 10.1056/NEJMoa1610020.<br />
|
| ［23］ |
Nemoto O, Furue M, Nakagawa H, et al. The first trial of CIM331, a humanized antihuman interleukin⁃31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double⁃blind, placebo⁃controlled study［J］. Br J Dermatol, 2016,174（2）:296⁃304. doi: 10.1111/bjd.14207.<br />
|
| ［24］ |
Khattri S, Shemer A, Rozenblit M, et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology［J］. J Allergy Clin Immunol, 2014,133（6）:1626⁃1634. doi: 10.1016/j.jaci.2014.03.003.<br />
|
